SINTX acquires SiNAPTIC Surgical to expand ceramic Additive Manufacturing solutions
SINTX Technologies, Inc, headquartered in Salt Lake City, Utah, USA, has issued an update highlighting progress following the company’s recent acquisition of medical ceramic Additive Manufacturing specialist SiNAPTIC Surgical, LLC, based in Broomfield, Colorado, USA.
TRUSTED BY INDUSTRY’S BIGGEST NAMES
Discover how we help leading brands shape the industry conversation
| Contact us |
In addition to the acquisition, the company has expanded its leadership team and undergone a restructuring programme.
“SINTX is now positioned to lead the next wave of innovation in medical technology,” said Eric Olson, Chairman and CEO. “In just six months, we have rebuilt the Company from the ground up – bringing in world-class leadership, streamlining operations, divesting non-core assets, and executing a focused commercialisation strategy designed to deliver breakthrough medical solutions and create substantial shareholder value. We are one of the only companies worldwide with both the intellectual property and manufacturing expertise to deliver advanced silicon nitride biomaterials in multiple formats to the medical device industry.”
Commercial product expansion and acquisition of SiNAPTIC
It was reported that the company continues to provide spinal interbody devices to CTL/ Amedica. To date, over 50,000 devices have been successfully implanted. Following the July 2025 acquisition of SiNAPTIC, the current portfolio of differentiated orthopaedic and spine technologies now includes 510(k)-cleared interbody spinal implants made from a proprietary silicon nitride ceramic biomaterial, along with foot and ankle fusion wedges, for which a new 510(k) premarket notification was submitted in July 2025.
Olson stated, “These next-generation implants combine the osteoconductive, antimicrobial, and imaging advantages of silicon nitride with the versatility of polymers already trusted by surgeons, all of which present significant opportunities for revenue and margin growth. The next six to twelve months will be even more transformative as we execute our strategic plans and redefine the medical device category.”
Expansion of leadership team
The acquisition of SiNAPTIC also brought a team of MedTech innovators to SINTX, significantly enhancing its depth and commercial capabilities. These include:
- Bryan Scheer, M.D. – Orthopaedic surgeon, MedTech entrepreneur, and founder of SiNAPTIC, now Chairman of the Clinical Advisory Board of SINTX
- Hugh Roberts – Co-founder of SiNAPTIC and industry veteran with a track record in product innovation and commercialisation, now Managing Director of Business Development
- Lisa Marie Del Re – experienced in launching and scaling orthopaedic sales channels, now Chief Commercial Officer
- Brian Hockett – expert in surgical R&D and engineering, now serving as Senior Vice President of Regulatory and Quality Affairs
Streamlined operations and strategic focus on medical devices
SINTX reported it had also undertaken a strategic restructuring over the past year aimed at focusing exclusively on high-margin, high-growth opportunities in orthopaedic and surgical markets. Key actions included the divestiture of non-core assets. In February 2025, SINTX sold its Maryland-based subsidiary, Technology Assessment & Transfer, Inc. (TA&T), eliminating associated liabilities and enabling greater strategic focus.
In August 2024, the company officially shut down its armour ceramics facility, ceasing further investment in non-core technologies and recognising a one-time impairment charge. It also exited from low-margin OEM manufacturing.
Future growth strategy – advancing innovation and scientific leadership
Looking ahead, SINTX said it will continue to build on its scientific foundation and IP portfolio with meaningful and long-term performance impact. Recent advancements include the company filing multiple new patents related to composite implant design, Additive Manufacturing, and antimicrobial ceramics.
